Editor's Correspondence |

Risedronate for the Prevention of Hip Fractures: Concern About Validity of Trials

Jutta Martha Halbekath; Stefanie Schenk; Andreas von Maxen, MD; Gabriele Meyer, PhD; Ingrid Mühlhauser, MD
Arch Intern Med. 2007;167(5):513-515. doi:10.1001/archinte.167.5.513-b.
Text Size: A A A
Published online


With concern, we read the trials conducted by Sato and colleagues comparing risedronate sodium with placebo in male patients with stroke1 and female patients with Alzheimer disease (AD).2

Both trials were conducted in a single center. Yet, patients (500 women with AD and 280 men with stroke) were recruited in only 3 months: the patients with AD in March and April 2003 and the patients with stroke in April and May 2003. Related to a third single-center trial with risedronate in 374 female patients with stroke at the same hospital that was published by the group in 2005,3 a correspondence letter4 expressed concern about the high frequency of recruitment, which was performed in only 4 months (between April and July 2003).3 In their reply, Sato and colleagues5 stated that their hospital is a specialized center for stroke and that they treat about 2800 patients with stroke per year. Even if these circumstances are taken into account, recruiting 280 male patients with stroke who meet all eligibility criteria in a single center in only 2 months appears implausible. This applies to an even greater extent to the 500 female patients with AD. Of note, Sato et al1,2 stated that only 1 physician (ie, Sato himself) did all AD diagnoses as well as the follow-up assessments of all 780 patients every 4 weeks.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles

The Rational Clinical Examination
Clinical Scenario